RA CAPITAL MANAGEMENT, L.P.
Institutional investor · Portfolio as of Q3 2024
Top Holdings81 positions
Stock | Shares | Value | Weight | Avg Buy | Est. P&L | Held | Conviction |
|---|---|---|---|---|---|---|---|
ASCENDIS PHARMA A/S | 9.7M | $1.4B | 16.7% | $92.75 | +55.92% | 24 qtrssince 2018-Q4 | Decreased 0 |
VAXCYTE INC | 8.7M | $992.9M | 11.4% | $40.85 | +176.94% | 18 qtrssince 2020-Q2 | Increased 66 |
JANUX THERAPEUTICS INC | 9.2M | $416.4M | 4.8% | $24.54 | +88.44% | 14 qtrssince 2021-Q2 | Unchanged 0 |
Legend Biotech Corp. Sponsored ADR | 7.5M | $365.8M | 4.2% | $57.21 | -13.88% | 9 qtrssince 2022-Q3 | Unchanged 0 |
RHYTHM PHARMACEUTICALS INC | 6.1M | $318.8M | 3.7% | $25.49 | +101.48% | 24 qtrssince 2018-Q4 | Unchanged 0 |
| 6.3M | $289.4M | 3.3% | $13.96 | +203.17% | 13 qtrssince 2021-Q3 | Increased 66 | |
TYRA BIOSCIENCES INC | 10.4M | $244.9M | 2.8% | $16.75 | +39.31% | 13 qtrssince 2021-Q3 | Unchanged 0 |
EVOLENT HEALTH INC | 8.5M | $240.8M | 2.8% | $26.66 | +9.88% | 5 qtrssince 2023-Q3 | Unchanged 0 |
EDGEWISE THERAPEUTICS INC | 8.9M | $237.8M | 2.7% | $18.24 | +43.04% | 3 qtrssince 2024-Q1 | Unchanged 0 |
BIOGEN IDEC INC | 1.2M | $229.6M | 2.6% | $218.66 | -4.35% | 11 qtrssince 2022-Q1 | Increased 63 |
DYNE THERAPEUTICS INC | 6.4M | $229.2M | 2.6% | $29.86 | +13.31% | 3 qtrssince 2024-Q1 | Increased 56 |
RXSIGHT INC | 3.9M | $193.6M | 2.2% | $20.41 | +137.79% | 13 qtrssince 2021-Q3 | Increased 56 |
BICARA THERAPEUTICS INC | 7M | $177.2M | 2.0% | $25.44 | 0.00% | 1 qtr | New 79 |
CLIMB BIO INC | 31.4M | $159.9M | 1.8% | $11.35 | -56.11% | 13 qtrssince 2021-Q3 | Unchanged 0 |
ARS PHARMACEUTICALS INC | 10.9M | $157.5M | 1.8% | $5.93 | +141.60% | 8 qtrssince 2022-Q4 | Unchanged 0 |
ARCELLX INC | 1.9M | $154.6M | 1.8% | $58.88 | +40.57% | 2 qtrssince 2024-Q2 | Increased 55 |
ARTIVA BIOTHERAPEUTICS INC | 9.9M | $152.2M | 1.8% | $14.01 | 0.00% | 1 qtr | New 69 |
WAVE LIFE SCIENCES LTD | 18.2M | $149.3M | 1.7% | $19.79 | -58.12% | 24 qtrssince 2018-Q4 | Unchanged 0 |
GERON CORP | 32.3M | $146.6M | 1.7% | $2.12 | +115.32% | 18 qtrssince 2020-Q2 | Decreased 0 |
VERONA PHARMA PLC | 5M | $144.1M | 1.7% | — | — | 17 qtrssince 2020-Q3 | Decreased 0 |
RA CAPITAL MANAGEMENT, L.P. manages $8.7B across 81 positions as of Q3 2024. Top holdings: ASND (16.7%), PCVX (11.4%), JANX (4.8%). Fund DNA: Balanced Allocator. HoldingsIntel Rating: 2/5.0.
Active quarter - 9 new positions, 6 exits, 9 increased. Top move: BCAX (NEW, conviction 79). Portfolio: $8.7B across 81 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer